+61.7%
CF vs GSK
+31.2%
+30.4%
-25.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.2% | -1.9% | -1.3% | -3.8% |
| 7D | +6.0% | -1.8% | +7.8% | +5.4% |
| 30D | +14.8% | -2.2% | +17.0% | +14.1% |
| 3M | +14.1% | -1.8% | +15.9% | +13.7% |
| 6M | +28.5% | -10.6% | +39.1% | +23.9% |
| YTD | +74.9% | +4.4% | +70.5% | +73.7% |
| 1Y | +61.7% | +30.4% | +31.3% | +76.1% |
| All | +61.7% | +31.2% | +30.4% | +76.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling